Positive statistically significant phase 2 clinical trial results of biodexa's newly-licensed erapa™ in familial adenomatous polyposis (fap) scheduled for presentation at the 2024 digestive disease week annual meeting

May 21, 2024 biodexa pharmaceuticals plc (“biodexa” or the “company”) positive statistically significant phase 2 clinical trial results of biodexa's newly-licensed erapa™ in familial adenomatous polyposis (fap) scheduled for presentation at the 2024 digestive disease week annual meeting overall 83% non-progression rate at 6 months statistically significant decrease in overall mean polyp burden at 6 months (p=0.04) biodexa pharmaceuticals plc, (nasdaq: bdrx), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce that results of a phase 2 clinical trial of erapa in familial adenomatous polyposis (“fap”) (nct04230499) are scheduled for presentation at the prestigious 2024 digestive disease week annual meeting in washington d.c.. carol burke, md, the principal investigator, will present the six month data in a podium presentation at the meeting.
BDRX Ratings Summary
BDRX Quant Ranking